Introduction
Methods
Systematic literature review
Network meta-analysis
Assessment of heterogeneity and inconsistency
Results
Study selection
Study and patient characteristics
First-line therapy progression-free survival/time to progression
Comparisons | HR (95% CrI) Fixed-effects model | HR (95% CrI) Random-effects model: vague priors | HR (95% CrI) Random-effects model: informative priors |
---|---|---|---|
Palbociclib + letrozole | 1 | 1 | 1 |
Single chemotherapy agents | |||
Paclitaxel | 0.59 (0.19–1.96) | 0.59 (0.07–4.83) | 0.63 (0.07–5.48) |
Docetaxel | 0.51 (0.14–2.03) | 0.50 (0.06–3.92) | 0.55 (0.07–4.24) |
Capecitabine (intermittent) |
0.28 (0.11–0.72)
| 0.27 (0.03–2.12) | 0.29 (0.03–2.45) |
Mitoxantrone |
0.28 (0.13–0.61)
| 0.27 (0.03–2.23) | 0.28 (0.03–2.28) |
Combination chemotherapy agents | |||
Paclitaxel + bevacizumab + everolimus | 0.99 (0.29–3.81) | 0.98 (0.12–8.43) | 0.93 (0.12–7.17) |
Paclitaxel + bevacizumab | 0.98 (0.31–3.38) | 0.96 (0.13–7.29) | 0.94 (0.10–8.65) |
Docetaxel + bevacizumab 15 mg | 0.65 (0.18–2.69) | 0.65 (0.09–4.70) | 0.72 (0.09–6.11) |
Docetaxel + bevacizumab 7.5 mg | 0.59 (0.16–2.40) | 0.58 (0.08–4.19) | 0.64 (0.08–5.36) |
Paclitaxel + sunitinib | 0.60 (0.18–2.14) | 0.60 (0.07–4.93) | 0.66 (0.09–5.00) |
Docetaxel + gemcitabine | 0.59 (0.20–1.91) | 0.59 (0.08–4.32) | 0.64 (0.08–5.20) |
Liposomal doxorubicin | 0.54 (0.14–2.29) | 0.53 (0.07–3.79) | 0.59 (0.07–4.99) |
Paclitaxel + gemcitabine | 0.51 (0.15–1.87) | 0.49 (0.06–4.21) | 0.56 (0.08–4.06) |
Paclitaxel + carboplatin | 0.53 (0.17–1.83) | 0.51 (0.06–4.35) | 0.57 (0.06–5.16) |
Docetaxel + capecitabine | 0.51 (0.19–1.49) | 0.50 (0.06–4.19) | 0.54 (0.08–3.90) |
Capecitabine + vinorelbine | 0.50 (0.16–1.72) | 0.49 (0.06–4.18) | 0.55 (0.06–4.98) |
Capecitabine + bevacizumab + vinorelbine | 0.48 (0.19–1.27) | 0.46 (0.06–3.76) | 0.50 (0.06–4.02) |
Docetaxel + epirubicin | 0.47 (0.20–1.19) | 0.46 (0.06–3.32) | 0.49 (0.06–4.15) |
Capecitabine + bevacizumab | 0.40 (0.16–1.06) | 0.39 (0.05–2.82) | 0.41 (0.06–2.99) |
Fluorouracil + epirubicin + cyclophosphamide |
0.33 (0.15–0.77)
| 0.32 (0.04–2.47) | 0.34 (0.03–3.34) |
Cyclophosphamide + methotrexate + 5-fluorouracil |
0.24 (0.11–0.57)
| 0.24 (0.03–2.11) | 0.25 (0.03–1.85) |
Model fit statistics | Residual deviance = 25.08 vs. 25 DIC = −0.02 | Residual deviance = 25.71 vs. 25 DIC = 0.11 Heterogeneity (SD) = 0.67 (0.01–4.53) | Residual deviance = 25.69 vs. 25 DIC = −0.05 Heterogeneity (SD) = 0.73 (0.02–3.64) |
Second-line therapy progression-free survival/time to progression
Comparisons | HR (95% CrI) Fixed-effects model | HR (95% CrI) Random-effects model: vague priors | HR (95% CrI) Random-effects model: informative priors |
---|---|---|---|
Palbociclib + Fulvestrant | 1 | 1 | 1 |
Single chemotherapy agents | |||
Doxorubicin | 0.80 (0.27–2.44) | 0.81 (0.22–3.02) | 0.82 (0.19–3.40) |
Docetaxel | 0.71 (0.24–2.13) | 0.69 (0.20–2.57) | 0.70 (0.17–2.76) |
Paclitaxel | 0.48 (0.16–1.44) | 0.49 (0.14–1.74) | 0.49 (0.12–1.98) |
Capecitabine (intermittent) |
0.28 (0.13–0.65)
|
0.29 (0.10–0.81)
|
0.29 (0.10–0.89)
|
Mitoxantrone |
0.26 (0.12–0.53)
|
0.26 (0.11–0.60)
|
0.26 (0.11–0.65)
|
Capecitabine (continuous) |
0.24 (0.11–0.56)
|
0.25 (0.09–0.70)
|
0.25 (0.09–0.78)
|
Pegylated liposomal doxorubicin |
0.19 (0.07–0.50)
|
0.20 (0.06–0.64)
|
0.19 (0.06–0.67)
|
Combination chemotherapy agents | |||
Paclitaxel + bevacizumab + gemcitabine | 0.89 (0.28–2.82) | 0.89 (0.23–3.49) | 0.91 (0.20–3.95) |
Docetaxel + sunitinib | 0.77 (0.26–2.36) | 0.75 (0.21–2.81) | 0.76 (0.18–3.12) |
Paclitaxel + bevacizumab | 0.72 (0.24–2.20) | 0.73 (0.20–2.68) | 0.74 (0.17–3.11) |
Paclitaxel + gemcitabine | 0.64 (0.22–1.94) | 0.67 (0.19–2.45) | 0.67 (0.16–2.77) |
Ixabepilone 40 mg + bevacizumab | 0.61 (0.18–2.05) | 0.62 (0.15–2.53) | 0.62 (0.13–2.84) |
Nab-paclitaxel + bevacizumab | 0.60 (0.20–1.87) | 0.60 (0.16–2.27) | 0.61 (0.13–2.61) |
Docetaxel + gemcitabine | 0.55 (0.19–1.61) | 0.57 (0.17–1.99) | 0.58 (0.15–2.29) |
Paclitaxel + motesanib | 0.51 (0.16–1.61) | 0.53 (0.14–2.13) | 0.53 (0.12–2.33) |
Docetaxel + capecitabine | 0.49 (0.17–1.38) | 0.51 (0.16–1.70) | 0.51 (0.14–1.96) |
Docetaxel + epirubicin | 0.45 (0.19–1.06) | 0.46 (0.17–1.28) | 0.47 (0.16–1.44) |
Paclitaxel + carboplatin | 0.44 (0.14–1.38) | 0.46 (0.13–1.67) | 0.46 (0.11–1.94) |
Ixabepilone 16 mg + bevacizumab | 0.45 (0.15–1.39) | 0.45 (0.12–1.71) | 0.46 (0.10–1.93) |
Capecitabine + sorafenib | 0.44 (0.17–1.14) | 0.45 (0.14–1.49) | 0.44 (0.14–1.54) |
Capecitabine + vinorelbine | 0.44 (0.15–1.28) | 0.47 (0.14–1.62) | 0.47 (0.13–1.85) |
Paclitaxel + epirubicin | 0.35 (0.11–1.16) | 0.36 (0.09–1.44) | 0.31 (0.07–1.37) |
Fluorouracil + epirubicin + cyclophosphamide |
0.31 (0.14–0.67)
|
0.32 (0.13–0.78)
|
0.31 (0.12–0.87)
|
Paclitaxel + capecitabine |
0.3 (0.09–0.98)
|
0.31 (0.08–1.23)
| 0.31 (0.07–1.44) |
Paclitaxel + epirubicin + capecitabine |
0.29 (0.09–0.95)
|
0.31 (0.08–1.16)
| 0.37 (0.08–1.70) |
Capecitabine + sunitinib |
0.23 (0.1–0.56)
|
0.24 (0.08–0.71)
|
0.23 (0.08–0.78)
|
Cyclophosphamide + methotrexate + 5-fluorouracil |
0.23 (0.1–0.51)
|
0.23 (0.09–0.61)
|
0.23 (0.09–0.68)
|
Model fit statistics | Residual deviance = 58.12 vs. 51 DIC = −4.11 | Residual deviance = 52.50 vs. 51 DIC = −4.36 Heterogeneity (SD) = 0.11 (0.01–0.26) | Residual deviance = 52.11 vs. 51 DIC = −4.63 Heterogeneity (SD) = 0.11 (0.01–0.26) |